Patrizia Froesch - Concepedia

Author

Patrizia Froesch

Swiss Group For Clinical Cancer Research ORCID

Also Known As

Froesch, Patrizia, P. Froesch, P.R. Froesch, Patrizia Froesch

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Swiss Group For Clinical Cancer Research University Hospital of Basel Kantonsspital Winterthur Institute of Oncology Research Kantonsspital Graubünden

About

Patrizia Froesch is an author at Swiss Group For Clinical Cancer Research specializing in oncology, radiation oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	485
2	Pathology	8	8	434
3	Immunology	3	3	69
4	Health Sciences	1	1	10
5	Pharmacology	1	1	39

Patrizia Froesch

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry Oliver Gautschi, Julie Milia, Thomas Filleron, Journal of Clinical Oncology	2017	349
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial Sacha I. Rothschild, Alfred Zippelius, E.I. Eboulet, Journal of Clinical Oncology	2021	336
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial Rafael Rosell, Urania Dafni, Enriqueta Felip, The Lancet Respiratory Medicine MedicinePathologyImmune Checkpoint InhibitorCancer TreatmentEgfr Mutations	2017	182
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma Yannis Metaxas, Gareth Rivalland, Laetitia Mauti, Journal of Thoracic Oncology Malignant DiseaseRadiation OncologyPalliative ImmunotherapyPleural Disease	2018	91
Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs) Sabine Schmid, Oliver Gautschi, Sacha I. Rothschild, Journal of Thoracic Oncology De Novo EgfrMedicinePathologyCancer TreatmentCancer Genetics	2016	72
SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial. Sacha I. Rothschild, Alfred Zippelius, E.I. Eboulet, Journal of Clinical Oncology Pd-l1 StatusSurgical OncologySakk 16/14MedicineAnti-pd-l1 Antibody Durvalumab	2020	39
Low prevalence of<i>Chlamydia psittaci</i>in ocular adnexal lymphomas from Cuban patients Elías Gracia, Patrizia Froesch, Luca Mazzucchelli, Leukemia & lymphoma/Leukemia and lymphoma Orbital EmzlLymphoid NeoplasiaMolecular Diagnostic TechniquesFish AnalysisOphthalmology	2006	38
Impact of the systematic introduction of low-cost bubble nasal CPAP in a NICU of a developing country: a prospective pre- and post-intervention study Rossano Rezzonico, Letizia M Caccamo, Valeria Manfredini, BMC Pediatrics	2015	37
Patterns of survival of follicular lymphomas at a single institution through three decades Annarita Conconi, Maddalena Motta, Francesco Bertoni, Leukemia & lymphoma/Leukemia and lymphoma	2010	34
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05) Francesco Zappa, C. Droege, Daniel Betticher, Lung Cancer First-line TherapySakk 19/05MedicineMetronomic TherapyPathology	2012	32

Page 1